Synaptagenx Clinical Trial Data

NuPathways gladly provides you with clinical trial data for our SynaptaGenX product. Helping people by offering them relief from addictive behaviors is our core mission. Health and well-being is our business, and your informed opinion is essential for their success. SynaptaGenX clinical trial data cover a host of different conditions, and each of the following items detail specific aspects of the condition.

This important information is free-of-charge; simply click on the Download link beside each trial document, and save to your local file system.

You and your acquaintances can greatly benefit from the many years of this painstaking, thoughtful, thorough and successful research that has already benefited thousands - offered here for free.

These clinical trial data demonstrate the core competency that SynaptaGenX brings to the fight against troublesome, oppressive, and sometimes dangerous addictions.

SynaptaGenX (SGX) Literature Support

Documents
Download	4-Page Technical Brochure on SynaptaGenX and Reward Deficiency Syndrome
Download	Comparison Chart of AMA Rates for SynaptaGenX vs. Placebo
Download	Comparison Chart of Relapse Rates for SynaptaGenX vs. Placebo

Clinical Trials
	Study Population	Type Study	Benefit	Reference/Author
Download	Cocaine Abusers	Controlled open label	Nine-fold decrease in AMA rate with SGX variant compared to controls	Cur Ther Res 43(6) 1204,1988 Blum et al.
Download	Alcoholic and Heroin Addicts	Open-label case study	We demonstrate for the first time that SGX intravenous administration reduces or "normalizes" aberrant electrophysiological parameters of the reward circuitry site	Postgraduate Medicine 122(6) 188, 2010 Miller et al.
Download	Psycho-stimulant abusers	randomized, triple-blind, placebo-controlled, crossover	SGX variant showed an increase of alpha waves and low beta wave activity in the parietal brain region one hour post administration	Postgraduate Medicine 122(6) 214,2010 Blum et al.
Download	Poly-drug abusers	Randomized Double-blind placebo -controlled	SGX variant significantly reduced stress response as measured by skin conductance, compared to patients receiving placebo.	Gene Therapy & Molecu lar Biology Blum et al.
Download	Obese Subjects	Open label pre vs post treatment	DNA customized SGX administration yielded significant results for weight loss, sugar craving reduction, appetite suppression, snack reduction, reduction of late night eating (all P<0.01 ), increased perception of overeating, enhanced quality of sleep, increased happiness (all P<0.05 ), and increased energy (P<0.001).	Adv Therp 25(9) 894,2008 Blum et al.
Download	Obese Subjects	Open label pre vs post treatment	DNA customized SGX administration yielded significant Pre- and post ad hoc analysis revealed a significant difference between the starting BMI and the BMI following an average of 41 days (28-70d) of SGX variant intake whereby 71.4% lost weight.	Gene Therapy & Mol Biol. 12,371,2008 Blum et al.
Download	Poly-Drug Addicts Court Mandated	Open label out-patient 12 month clinical trial	SGX variant after 1 year yielded a significant decrease in depression, anger, anxiety, drug craving, increased energy. Drop out rate for alcoholics was only 7%.	Adv Therp 24(2), 402,2007 Chen et al.
Download	Methadone Addicts	Open label out-patient 12 month clinical trial comparison to non-treatment	The average number of days of compliance of being drug free utilizing Naltrexone in 1000 patients without SGX variant using rapid detoxification method is only 37 days. With SGX patients were relapse free for an average of 262 days (P<0.0001).	Med Hyp 63,538,2004 Chen et al.
Download	Poly-Drug Addicts	Randomized double-blind placebo controlled	With SGX variants significantly improved Physical Scores and BESS Scores (behavioral, emotional, social and spiritual). *After detoxification there was a six-fold decrease in AMA* rates when comparing SGX variant vs. placebo groups. In this inpatient treatment experience SGX variant facilitated the rate of recovery and allowed patients to respond more fully and more quickly to the behavioral goals of the program.**	Alcohol 5,481,1988 Blum et al.
Download	Detoxified Poly-Drug Addicts	In-patient 30 day double-blind controlled	SGX variant patients as compared to controls (no SGX) had a lower Building Up To Drink Score (BUD), required no benzodiazepines (0 vs. 94%), ceased tremors at 72 hours as compared to 96 hours, had no severe depression on the MMPI compared to 24% in the control group.	International Journal of Addictions 23(9), 991,1988. Blum et al.
Download	DUI Outpatient Offenders Alcohol and Cocaine	One year open label controlled (vitamin) clinical trial.	SGX variants significantly reduced relapse rates and enhanced recovery in DUI outpatient offenders over a 10 week period. After ten months SGX compared to controls revealed a 73% recovery rate in alcoholics and a 53% recovery rate in cocaine addicts.	Journal of Psychoactive Drugs, 22(2) 173,1990. Brown et al.
Download	Healthy volunteers	30 day open label pre-post evaluation	SGX variant induced a significant enhancement of focus as measured by P300 wave and computerized performance tasks.	Clin- Electroencephalogr. 28(2) 68,1997 Defrance et al.